Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

Publisher: La Merie Publishing
Pages: 74
Format: PDF and Online
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0017
Release Date: May of 2016

300.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-CD20 Antibodies 2016 updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting CD20 in comparison with originator anti-CD20 antibodies to treat solid tumors as well as inflammatory diseases as of May 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in development of CD20 targeting biosimilar and biosuperior antibodies for treatment of hematologic malignancies, rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

Table of Contents

1.         2015 Sales of Anti-CD20 Antibodies

2.         Originator Anti-CD20 Antibodies
Rituxan / MabThera Approved Indications & Pipeline
Gazyva Approved Indications & Pipeline
Arzerra Approved Indications and R&D Pipeline
Zevalin Approved Indications

3.         Biosuperior Anti-CD20 Antibodies
3rd Generation Anti-CD20 Antibodies
Bispecific Anti-CD20 Antibodies
Anti-CD20 Antibody-Drug Conjugates, Immunotoxins & Immunocytokines

4.         Biosimilar Anti-CD20 Antibodies
Rituxan/MabThera Biosimilar Antibodies:
-           Developments in Regulated Markets
-           Developments in Less Regulated Markets
Arzerra Biosimilar Antibodies

5.         Corporate Anti-CD20 Biosimilar & Biosuperior Antibody Pipelines

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up